ACADIA Pharmaceuticals Spotlights Alzheimer's Psychosis Pipeline, NUPLAZID and DAYBUE Growth
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call Transcript
Acadia Pharmaceuticals (ACAD) Lags Q1 Earnings and Revenue Estimates
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D.
CSLLY vs. ACAD: Which Stock Is the Better Value Option?
Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
CSLLY vs. ACAD: Which Stock Should Value Investors Buy Now?
Mark Schneyer Sells 2,709 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock
Will Acadia (ACAD) Beat Estimates Again in Its Next Earnings Report?
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of “Moderate Buy” from Brokerages
Why Is Acadia (ACAD) Down 12.9% Since Last Earnings Report?
Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback
Acadia Pharmaceuticals upgraded on improve risk-reward profile following pullback
ACADIA Pharmaceuticals Maps Key CNS Readouts: Remlifanserin ADP Data Due Aug–Oct, ACP-211 Next Year
ACADIA Pharmaceuticals Inc. $ACAD Shares Sold by First Trust Advisors LP
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
JAZZ or ACAD: Which Is the Better Value Stock Right Now?
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised)
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
Acadia Pharmaceuticals: Undervalued Despite Robust Revenues From Approved Drugs, With Pipeline Kicker
ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call Transcript
Acadia Pharmaceuticals (ACAD) Q4 Earnings Top Estimates
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Rhumbline Advisers Buys 24,463 Shares of ACADIA Pharmaceuticals Inc. $ACAD
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ACADIA Pharmaceuticals Inc. $ACAD Shares Purchased by GSA Capital Partners LLP
LSV Asset Management Sells 192,800 Shares of ACADIA Pharmaceuticals Inc. $ACAD
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of “Moderate Buy” from Brokerages
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
Alger Weatherbie Specialized Growth Fund Q4 2025 Winners And Laggards
Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
Why Acadia (ACAD) is Poised to Beat Earnings Estimates Again
John Hussman's Strategic Moves: Qualcomm Inc. Takes Center Stage with 1.13% Portfolio Impact
FTRE or ACAD: Which Is the Better Value Stock Right Now?
Hussman Strategic Advisors Inc. Purchases Shares of 126,000 ACADIA Pharmaceuticals Inc. $ACAD